Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer
CCO Oncology Podcast
English - December 17, 2021 23:00 - 12 minutes - 11.8 MBCourses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:
Transitioning from second- to third-line therapyFactors in selecting among available therapiesKey predictors of improved outcomes with regorafenib vs TAS-102Presenters:
Chiara Cremolini, MD, PhD
Medical Oncologist
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Professor
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy
Teresa Macarulla, MD, PhD
Medical Oncologist
Head, Gastrointestinal and Endocrine Tumors Unit
Division of Medical Oncology
Vall d´Hebrón Institute of Oncology
Barcelona, Spain
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Follow along with the slideset:
https://bit.ly/3FjekMo
Link to full program:
https://bit.ly/33yrIyh